FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to a compound having the structure:
or to its pharmaceutically acceptable salt. Invention also relates to a method of treating a condition in an animal using said compound which binds LANCL2.
EFFECT: technical result is a novel compound which can be used in medicine for treating an infectious disease, an autoimmune disease, diabetes and a chronic inflammatory disease.
15 cl, 42 dwg, 2 tbl, 24 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICINES BASED ON LANTIONINE SYNTHETASE OF C-LIKE PROTEIN 2 | 2015 |
|
RU2741576C2 |
| MEDICINAL PRODUCTS BASED ON LANTHIONINE SYNTHETASE C-LIKE 2 PROTEIN | 2020 |
|
RU2768888C1 |
| COMPOUND WS727713 | 2005 |
|
RU2407785C2 |
| COMPOSITIONS TO TREAT INFLAMMATORY BOWEL CONDITION | 2008 |
|
RU2495121C2 |
| COP1 FOR TREATMENT OF INFLAMMATORY DISEASES OF INTESTINE | 2004 |
|
RU2339397C2 |
| HUMANISED ANTIBODIES SPECIFIC FOR HSP65-DERIVED PEPTIDE-6, METHODS AND USES THEREOF | 2010 |
|
RU2596925C2 |
| QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | 2015 |
|
RU2760686C2 |
| USE OF MICROBIAL COMMUNITIES FOR THE TREATMENT OF HUMANS AND ANIMALS | 2017 |
|
RU2758387C2 |
| METHOD OF TREATING INFLAMMATION IN NEURONAL TISSUE WITH USING MONOCLONAL ANTIBODY AND ITS BINDING FRAGMENT | 2007 |
|
RU2565391C2 |
| METHOD OF PAIN MANAGEMENT AND NEURON TISSUE INFLAMMATION TREATMENT WITH USING IL-31 ANTAGONISTS | 2007 |
|
RU2440130C2 |
